Standardizing myeloma diagnosis, treatment, and management across Canada
Recognizing the need for medical consensus on the diagnosisThe process of identifying a disease by its signs and symptoms., treatment, and management of myeloma in Canada across all provinces, Myeloma Canada led the development of the first Canadian evidence-based treatment guidelines in collaboration with a team of Canadian myeloma experts.
Managed and financed by Myeloma Canada, the Canadian Evidence-based Myeloma Canada Consensus Guidelines is a series of peer-reviewed publications that are aimed to improve, standardize, and educate physicians on the management of myeloma in Canada.
What is the purpose of creating these guidelines?
As there were no unified Canadian national guidelines for the diagnosis and treatment of multiple myeloma, there was a need for evidence-based national recommendations.
Although some provinces do have their own guidelines, the Canadian national guidelines take provincial variations in access and funding into consideration. The overarching goal is to provide Canadian clinicians with concise diagnostic recommendations upon which therapeutic decisions can be made. The focus is on relevance, applicability, and the use of the various tests available in routine Canadian practice.
The guidelines
First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium
Published October 2024 in Clinical Lymphoma, Myeloma & LeukemiaConsensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders
Published February 2020 in Clinical Lymphoma, Myeloma & LeukemiaManagement of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care
Published January 2022 in ClinicalInvolving direct observation of a patient. Lymphoma, Myeloma & Leukemia
First line treatment of newly diagnosed transplant ineligible multiple myeloma
Published February 2023 in Clinical Lymphoma, Myeloma & Leukemia